Medtronic picks SurModics hydrophilic technology

qiangzi

Medtronic picks SurModics hydrophilic technology
/ H; s# S5 W% a4 ]" M2 e
Tuesday, March 6, 2012

: u6 o; O9 G* ]4 u! @. m( `9 `Eden Prairie, MN - SurModics, a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, announced that its proprietary hydrophilic technology is being used on Medtronic’s U.S. Food and Drug Administration (FDA) approved Resolute Integrity Drug-Eluting Stent (DES) delivery system for the treatment of coronary artery disease (CAD). “We are extremely pleased that our hydrophilic coating was selected for use on the delivery catheter of Medtronic’s Resolute Integrity DES delivery system. SurModics values the long-standing relationship with Medtronic and remains steadfast in complementing the deliverability of the Resolute Integrity DES through our advanced hydrophilic coating platforms,” said Gary Maharaj, president and CEO of SurModics